Endothelial dysfunction in diabetes
By A. D. De Vriese, T. Verbeuren, J. van de Voorde, N. Lameire, P. Vanhoutte. British Journal of Pharmacology, 2000
1,252 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Clinical Biochemistry, Physiology
View Paper: https://www.semanticscholar.org/paper/d767d605ae6fc6c7e9e83f6090b4e9a113561fef
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Physiology
Citations in the corpus
- Endothelial dysfunction and vascular disease – a 30th anniversary update (2017, background): “The endotheliumdependent relaxations to acetylcholine are blunted in a number of arteries from diabetic animals (Tesfamariam 1994, De Vriese et al. 2000).”
- Mitochondrial Dysfunction in Diabetes: From Molecular Mechanisms to Functional Significance and Therapeutic Opportunities (2010, positive): “Impaired endothelium-dependent vasodilation has been demonstrated in various vascular beds of animal models of diabetes and humans with type 1 and type 2 diabetes (80).”
- New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. (2003, background): “Vascular endothelial cells are an important target of hyperglycemic damage, but the mechanisms underlying this damage are not fully understood (5).”
- Endothelial Dysfunction and Diabetes: Effects on Angiogenesis, Vascular Remodeling, and Wound Healing (2012, background): “Studies aimed at combination therapies could prove beneficial to enhance protection against vascular complications during diabetes.”
- Endothelial dysfunction in diabetes mellitus (2007, neutral): “…NIDDM +EDVD,(signifi cant) et al 2002 followed by 20 mg daily for 312) van de Ree et al 2001 6-week Tx with simvastatin 17 pt. NIDDM No effect 40 mg/daily Dumont et al 2001 Pravastatin (20 mg/kg/day) Experimental rats restores endothelial function for 2 wks Tsunekawa et al 2001 cerivastatin (0.15…”
- The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors (2002, background): “…are crucially altered by the metabolic milieu that characterizes diabetes mellitus, tipping the delicate balance toward atheroma formation, platelet aggregation, and thrombus formation (Keen et al., 1999; Tooke and Goh, 1999; De Vriese et al., 2000; Schaper et al., 2000; Standl and Schnell, 2000).”